Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Nuwellis Inc — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $15.58 (market cap $7.11B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 3231.8× Nuwellis Inc's market cap, and Norwegian Cruise Line Holdings Ltd is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Norwegian Cruise Line Holdings Ltd for 68 Days and Nuwellis Inc for 26 Days on average.
| NCLH | NUWE | |
|---|---|---|
Market Cap | $7.11B | $2.20M |
Volume | 22,683,268 | 121,544 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.02 | $146.65 |
52-Week Low | $14.12 | $0.68 |
Typical Hold Time | 68 Days | 26 Days |
Enterprise Value | $21.93B | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NCLH trades at $15.57, up 3.46% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.48, beating expectations, and expects Q3 results to exceed guidance. Valuation metrics appear attractive with a P/E of 9.39 and P/S of 0.75. Revenue has grown from $4.8B in 2022 to $9.83B in 2025, though net income margin declined to 4.3% from 9.6% in 2024.
The outlook is mixed: analyst consensus is bullish with a $20.86 price target, but the company faces yield pressure and high debt levels. Investment opportunity lies in continued operational recovery and compelling valuation, while risks include Caribbean pricing pressure and significant leverage that could constrain financial flexibility.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
